Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Sees Significant Increase in Short Interest

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 119,700 shares, a growth of 93.4% from the February 13th total of 61,900 shares. Based on an average trading volume of 4,130,000 shares, the short-interest ratio is presently 0.0 days. Currently, 6.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Renaissance Technologies LLC bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,611 shares of the company’s stock, valued at approximately $34,000. Renaissance Technologies LLC owned about 0.39% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ CYCN opened at $2.53 on Friday. The stock has a market capitalization of $6.86 million, a price-to-earnings ratio of -2.07 and a beta of 2.09. The business has a 50-day moving average of $3.05 and a 200-day moving average of $2.90. Cyclerion Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $9.47.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.22 earnings per share for the quarter. The company had revenue of $1.81 million during the quarter.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.